［B1－Ala，B2－Ala］－胰岛素：受体结合特性及生物活力研究

本文报道了［Ｂ１～Ａｌａ,Ｂ２－Ａｌａ］－胰岛素与人胎盘细胞膜胰岛素受体结合的特性和体外生物活力,并与胰岛素进行比较。在３７℃和杆菌肽存在下,１２５Ｉ－［Ｂ１－Ａｌａ,Ｂ２－Ａｌａ］－胰岛素和１２５Ｉ－胰岛素与人胎盘细胞膜作用依赖于反应时间,反应６分钟到达平衡,此时,［Ｂ１－Ａｌａ,Ｂ２－Ａｌａ］－胰岛素和胰岛素与胰岛素受体的最大结合分别为每毫克膜蛋白结合６．４４ｆｍｏｌ和３．４７ｆｍｏｌ：达到平衡一半所需时间（Ｔ１／２）分别为１９秒和２５秒。用１２５Ｉ－［Ｂ１－Ａｌａ,Ｂ２－Ａｌａ］－胰岛素作为放射配体进行竞争性结合研究,从ＩＣ（５０）得［Ｂ１－Ａｌａ,Ｂ２－Ａｌａ］胰岛素的受体结合活力为胰岛素的１３９．６％。Ｓｃａｔｏｈａｒｄ分析求得;［Ｂ１－Ａｌａ,Ｂ２－Ａｌａ］－胰岛素与高亲和和低亲和结合位点的结合常数在４℃时分别为５．８８×１０８Ｌ／ｍｏｌ和７．６３×１０５Ｌ／ｍｏｌ,而胰岛素分别为４．８３×１０８Ｌ／ｍｏｌ和３．３９×１０５Ｌ／ｍｏｌ。促脂肪细胞生成脂的实验表明：［Ｂ１－Ａｌａ,Ｂ２－Ａｌａ］－胰岛素的活力为胰岛素的１３０％。     

高受体结合和低免疫原性的[Bl—Ala,B2—Ala]—胰岛素

通过化学半合成从天然猪胰岛素得到［Ｂｌ－Ａｌａ,Ｂ２－Ａｌａ］－胰岛素,这一胰岛素类似物经聚丙烯酰胺凝胶电泳和ＨＰＬＣ鉴定证明是均一的,氨基酸组成与理论值相符,生物活性测定结果表明：［Ｂｌ－Ａｌａ,Ｂ２－Ａｌａ］－胰岛素的体内活力与天然猪胰岛素相同,而与人胎盘细胞膜胰岛素受的结合能力为天然猪胰岛素的１３２％。这一结果进一步说明胰岛素Ｂ链Ｎ端肽段参予与受体相互作用,此外,［Ｂｌ－Ａｌａ,Ｂ２－Ａｌａ     

[B_1Ala,B_2Ala,B_3Lys]-胰岛素的制备和生物活性(英文)

本文报道了胰岛素分子中Ｂ１～３序列（Ｐｈｅ－Ｖａｌ－Ａｓｎ）为Ａｌａ－Ａｌａ－Ｌｙｓ取代的胰岛素类似物制备及其生物性质。［Ｂ１Ａｌａ,Ｂ２Ａｌａ,Ｂ３Ｌｙｓ］－胰岛素仍保留天然胰岛素的全部体内活性和受体结合能力,但体外促脂肪生成活性和免疫活性分别只为胰岛素的７０％和０．８８％。本文还就胰岛素Ｂ链Ｎ端肽段对其结构和功能的影响进行了讨论。     

[B1Ala,B2Al2,B3Lys]—胰岛素的制备和生物活性

本文报道了胰岛素分子中Ｂ１￣３序列（Ｐｈｅ－Ｖａｌ－Ａｓｎ）为Ａｌａ－Ａｌａ－Ｌｙｓ取代的胰岛素类似物制备及其生物性质。［Ｂ１Ａｌａ,Ｂ２Ａｌａ,Ｂ３Ｌｙｓ］－胰岛素仍保留天然胰岛素的全部体内活性和受体结合能力,但体外促脂肪生成活性和免疫活性分别只为胰岛素的７０％和０．８８％。本文还就胰岛素Ｂ链Ｎ端肽段对其结构和功能的影响进行了讨论。     

［B3－Lys］－胰岛素的研究：受体结合及生物活性

本文用１２５Ｔ－［Ｂ３－Ｌｙｓ］－胰岛素和１２５Ⅰ－胰岛素研究了［Ｂ３－Ｌｙｓ］－胰岛素和胰岛素与人胎盘细胞膜（ＨＰＭ）胰岛素受体结合特性并进行了比较。实验结果表明［Ｂ３－Ｌｙｓ］－胰岛素与ＥＰＭ胰岛素受体结合能力比天然猪胰岛素高。由竞争取代曲线得到的［Ｂ３－Ｌｙｓ］－胰岛素和猪胰岛素的ＩＣ（５０）值分别为０．６５和１．１１ｎｍｏｌ／Ｌ。经Ｓｃａｔｃｈａｒｄ分析得出［Ｂ３－Ｌｙｓ］－胰岛素与ＨＰＭ胰岛素受体中高亲和位点和低亲和位点结合的亲和常数分别为１．７２×１０９和２．２７×１０６Ｌ／ｍｏｌ,而猪胰岛素分别为１．２６×１０９和１．４７×１０６／ｍｏｌ。促脂肪细胞合成脂肪实验结果表明［Ｂ３－Ｌｙｓ］－胰岛素也同样具有比天然猪胰岛素更高的离体生物活力,ＥＣ（５０）分别为０．１７５和０．３０１ｎｍｏｌ／Ｌ。可见［Ｂ３－Ｌｙｓ］－胰岛素的受体结合能力和高体生物活力都为猪胰岛素的１．７倍。     

高活力胰岛素研究：B3—Lys猪胰岛素的结晶及初步晶体学分析

用化学半合成方法制备的Ｂ３—Ｌｙｓ猪胰岛素（Ｂ３ＫＰＩ）具有与天然猪胰岛素相同的体内生物活力,但其体外生物活力及受体结合活力比天然猪胰岛素高。本文报道Ｂ３ＫＰＩ的晶体生长,初步晶体学分析及衍射数据与处理。Ｂ３ＫＰＩ晶体的衍射分辨率可以达到２．１Ａ（１Ａ＝０．１ｎｍ）,空间群为Ｒ３,晶胞参数为：ａＨ＝ｂＨ＝８２．２３ＡＣＨ＝３４．１７Ａ．收集了一套２．１Ａ分辨率的衍射数据,数据完全度为８１％,Ｒｍｅｒｇｅ为２．９％。     

B8Gly在胰岛素结构模体中的可能作用

在胰岛素结构模体ｎ１－Ｃｙｓ－Ｇｌｙ－Ｘ１０－Ｃｙｓ－ｎ２－Ｃｙｓ－Ｃｙｓ－Ｘ３－Ｃｙｓ－Ｘ８－Ｃｙｓ－ｎ３中,有７个绝对保守的氨基酸残基,只有位于Ｂ８位的是Ｇｌｙ。通过定点突变将其改变为Ａｌａ,得到「Ｂ８Ａｌａ」人胰岛素,其受体结合能力和体内生物活力分别为天然猪胰岛素的２．５％和１０％。「Ｂ８Ａｌａ」人胰岛素和重组人胰岛素的远紫外圆二色谱比较表明,「Ｂ８Ａｌａ」人胰岛素的α－螺旋的相对含量有一家     

[B3—Lys]—胰岛素的研究：受体结合及生物活性

本文用＾１２５Ｉ－［Ｂ３－Ｌｙｓ］－胰岛素和＾１２５Ｉ－胰岛素研究了［Ｂ３－Ｌｙｓ］－胰岛素和胰岛素与人胎盘细胞膜胰岛素受体结合物性并进行了比较。实验结果表明［Ｂ３－Ｌｙｓ］－胰岛素与ＨＰＭ胰岛素受体结合能力比天然猪胰岛素高。由竞争取代曲线得到的［Ｂ３－Ｌｙｓ］－胰岛素和猪胰岛素的ＩＣ（５０）值分另为０．６５和１．１１ｎｍｏｌ／Ｌ。经Ｓｃａｔｃｈａｒｄ分别得出［Ｂ３－Ｌｙｓ］－胰岛素与ＨＰＭ胰岛素     

金属内肽酶底物Glutaryl－Ala－Ala－Phe－2NA的合成

文本以苯丙萘胺（Ｐｈｅ－２ＮＡ）为原料,通过Ｂｏｃ－Ｎ－羟基丁二酰亚胺活化酯法合成了金属内肽酶底物Ｇｌｕｔａｒｙｌ－Ａｌａ－Ａｌａ－Ｐｈｅ－２ＮＡ     

胰岛素蛋白质工程：高活性［B10Asp］人胰岛素

用基因定位突变方法将胰岛素Ｂ链第１０位的Ｈｉｓ变为Ａｓｐ,获得高活力胰岛素──［Ｂ１０Ａｓｐ］人胰岛素。其受体结合能力和离体生物活力分别为猪胰岛素的２６２％和２３５％;体内生物活力也明显高于猪胰岛素;它的促细胞生长能力为猪胰岛素的１７４％。     

[B2-Lys]-胰岛素的制备与性质

本文报道了用化学半合成途径从天然猪胰岛素制备[B2-Lys]-胰岛素的过程。人胎盘细胞膜胰岛素受体结合试验表明:[B2-Lys]-胰岛素的受体结合能力只有天然胰岛素的80％,降兔血糖作用与时间关系的结果表明它没有长效作用。本文还对这些结果进行了讨论。     

Receptor binding and biological activity of [SerB24]-insulin, an abnormal mutant insulin

[SerB24]-insulin, the second structurally abnormal mutant insulin, and [SerB25]-insulin were semisynthesized and were studied for receptor binding and biological activity. Receptor binding and biological activity determined by its ability to increase 2-deoxy-glucose uptake in rat adipocytes were 0.7-3% of native insulin for [SerB24]-insulin and 3-8% for [SerB25]-insulin. Negative cooperative effect of these analogues was also markedly decreased. Immunoreactivity of [SerB24]-insulin was decreased whereas that of [SerB25]-insulin was normal. Markedly decreased receptor binding of [SerB24]-insulin appeared to be due to substitution of hydrophobic amino acid, Phe, with a polar amino acid, Ser, at B24.     

Impaired negative cooperativity of the semisynthetic analogues human [LeuB24]- and [LeuB25]-insulins

Several semisynthetic analogues of human insulin were prepared by enzyme-assisted coupling of synthetic octapeptides to the C-terminal of porcine desoctapeptide insulin. We report the receptor-binding and biological properties of [Leu^B24]- and [Leu^B25]-insulins, one of which has the same sequence as a “mutant” insulin recently found in a diabetic patient (Tager, H. et al.(1979) Nature $\text{28}$:121–125). [Leu^B24]- and [Leu^B25]-insulins had, respectively, 8–12% and 0.9–1.1% of the binding affinity of human insulin, and 11% and 2.7% of its potency in stimulating lipogenesis in isolated rat fat cells. Neither one was an antagonist of the biological effects of native insulin. While the ability of [Leu^B24]-insulin to induce negative cooperativity was clearly impaired, that of [Leu^B25]-insulin was almost abolished. [Leu^B25]-insulin was also a potent antagonist of the negative cooperativity induced by native insulin.     

Supernormal insulin: [D-PheB24]-insulin with increased affinity for insulin receptors

[D-Phe^B24]- and [D-Phe^B25]-human insulin were semisynthesized from porcine insulin by enzyme assisted coupling method. Receptor binding ability of [D-Phe^B24]- and [D-Phe^B25]-insulin was 180% and 4%, respectively, of that of human insulin. Increased affinity of [D-Phe^B24]-insulin was ascribed to markedly decreased dissociation rate in binding to human cultured lymphocytes. Negative cooperative effect of [D-Phe^B24]insulin was also increased to twice of that of human insulin. Biological activity of these analogues was assessed by 2-deoxy-glucose uptake studies in isolated adipocytes and the ability of [D-Phe^B24]- and [D-Phe^B25]-insulin was 140% and 4%, respectively, of that of human insulin. These findings suggest that B25 L-Phe is more crucial for receptor binding and that [D-Phe^B24]-insulin is the first semisynthetic insulin to show increased affinity for insulin receptors.     

[B10,22-Asp,B25-Tyr-NH2]-去β链C端五肽胰岛素的合成和性质

本文报道了[B10,22-Asp,B25-Tyr-NH2]-去B链羧端五肽胰岛素的制备及其生物活性。结果表明,这一类似物的生物活力比去五肽胰岛素(DPI)的活力高一倍,但却比Gerald所报道的[B10-Asp,B25-Tyr-NH_2]-DPI的活力低很多,说明后者的高活性可能依赖于分子中B22-Arg的存在。     

Hydrolysis of monomolecular layers of synthetic sphingomyelins by sphingomyelinase of Staphylococcus aureus.

Human [LeuB-24]- and [LeuB-25]-insulins were semi-synthesized from porcine insulin by an enzyme-assisted coupling method. The receptor-binding ability of [LeuB-24]- and [LeuB-25]-insulins was 30--48% and 2--5% respectively of that of human insulin. There was no significant difference in degradation between human insulin and these analogues on incubation with isolated adipocytes. The decreased affinity of these analogues was due to an increased dissociation rate rather than a change in the association rate of their binding to human cultured lymphocytes. The negative co-operative effect of [LeuB-24]- and [LeuB-25]-insulin was decreased to 50 and 1% respectively of that of human insulin at a concentration of 100 ng/ml. The ability of [LeuB-24]- and [LeuB-25]-insulin to stimulate 2-deoxyglucose uptake in isolated rat adipocytes was 35 and 4% respectively of that of human insulin. These analogues did not have an antagonistic effect on the biological activity of human insulin. The immunoreactivity of [LeuB-25]insulin was similar to that of porcine or human insulin, whereas [LeuB-24]insulin demonstrated decreased binding to anti-(porcine insulin) antibodies. These findings suggest that B-chain phenylalanine-25 residue is more crucial for receptor binding and negative co-operativity, whereas the B-chain phenylalanine-24 residue may play a more important role in binding to anti-insulin antibody.     

Semisynthetic des-(B27-B30)-insulins with modified B26-tyrosine

Semisynthetic des-(B27-B30)-insulins containing modified B26-tyrosine residues were prepared to refine the understanding of the importance of position B26 with regard to biological and structural properties of the hormone. The following shortened insulin analogues were synthesized by trypsin-catalysed peptide-bond formation between the C-terminal amino acid ArgB22 of des-(B23-B30)-insulin and synthetic tetrapeptides as amino components: des-(B27-B30)-insulin, des-(B27-B30)-insulin-B26-methyl ester, -B26-carboxamide with varying C-terminal hydrophobicity of the B-chain, and [Tyr(NH2)B26]-, [Tyr(NO2)B26]-, [Tyr(I2)B26]-, [D-TyrB26]des-(B27-B30)-insulin-B26-carboxamide containing non-proteinogenic amino acids in position B26. Starting from insulin and an excess of synthetic Gly-Phe-Phe-Tyr-OMe as nucleophile, des-(B27-B30)-insulin-B26-methyl ester--the formal transpeptidation product at ArgB22--was formed in one step. Biological in vitro properties (binding to cultured human IM-9 lymphocytes, relative lipogenic potency in isolated rat adipocytes) of all semisynthetic analogues are reported, ranging from slightly decreased to two-fold receptor affinity and nearly three-fold biopotency relative to insulin. If the C-terminal tetrapeptide B27-B30 is removed, full relative insulin activity is still preserved, while the shortening results in the loss of ability to associate in solution. Only after carboxamidation or methyl esterification of TyrB26 the self-association typical of native insulin can be observed, and the CD-spectral effects in the near UV spectrum related to association and hexamerization of the native hormone are qualitatively reestablished. The results of this investigation underline the importance of position B26 to the modulation of hormonal properties and solution structure of the shortened insulins.     

Insulin analogues with modifications at position B26. Divergence of binding affinity and biological activity

In this study, we prepared several shortened and full-length insulin analogues with substitutions at position B26. We compared the binding affinities of the analogues for rat adipose membranes with their ability to lower the plasma glucose level in nondiabetic Wistar rats in vivo after subcutaneous administration, and also with their ability to stimulate lipogenesis in vitro. We found that [NMeHisB26]-DTI-NH 2 and [NMeAlaB26]-DTI-NH 2 were very potent insulin analogues with respect to their binding affinities (214 and 465%, respectively, compared to that of human insulin), but they were significantly less potent than human insulin in vivo. Their full-length counterparts, [NMeHisB26]-insulin and [NMeAlaB26]-insulin, were less effective than human insulin with respect to binding affinity (10 and 21%, respectively) and in vivo activity, while [HisB26]-insulin exhibited properties similar to those of human insulin in all of the tests we carried out. The ability of selected analogues to stimulate lipogenesis in adipocytes was correlated with their biological potency in vivo. Taken together, our data suggest that the B26 residue and residues B26-B30 have ambiguous roles in binding affinity and in vivo activity. We hypothesize that our shortened analogues, [NMeHisB26]-DTI-NH 2 and [NMeAlaB26]-DTI-NH 2, have different modes of interaction with the insulin receptor compared with natural insulin and that these different modes of interaction result in a less effective metabolic response of the insulin receptor, despite the high binding potency of these analogues.     

胰岛素蛋白质工程：[B9Glu]人胰岛素

用基因定位突变方法将胰岛素Ｂ链第９位的Ｓｅｒ改为Ｇｌｕ。获得速效胰岛素─—［Ｂ９Ｇｌｕ］人胰岛素．它的受体结合能力和体内生物活力分别为猪胰岛素的２１％和４０％。